Login with your work email address to view charts. No credit card required.
| Art Unit: | 1641 — Drug, bio-affecting and body treating compositions |
|---|---|
| Group: | 1640 — Immunology including antibodies, B&T lymphocytes, antigen presenting cells and Gram-positive/Negative Bacteria, Parasitic and Fungal Immunology |
| Classes: |
424 — Drug, bio-affecting and body treating compositions 530 — Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof 435 — Chemistry: molecular biology and microbiology 514 — Drug, bio-affecting and body treating compositions |
| Phone: | (571) 272-0839 |
| Email: | misook.yu@uspto.gov |
| Location: | VA 22314 |
| Title: | Supvy Pat Examnr Gen Chem |
| Service: | 24 years |
| Grade: | GS-15 |
| 3-Year Grant rate: | 0% over 25 cases |
|---|---|
| Difficulty: | Extremely Hard |
| Difficulty Percentile: | 99th
|
With Examiner Yu (SPE), you have a 0% chance of getting an issued patent by 3 years after the first office action. Examiner Yu (SPE) is an extremely hard examiner and in the 99th percentile across all examiners (with 100th percentile most difficult).
Below is the grant rate timeline for Examiner Yu (SPE), where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.
Examiner Yu (SPE)'s grant rate is lower than that of Art Unit 1641 and lower than that of the USPTO.
| Average Office Actions Per Grant | |
|---|---|
| Examiner Yu (SPE) | 0.7 |
| Art Unit 1641 | 1.8 |
Subscribe to Premium Examiner Statistics for unlimited access to our examiner statistics.
Subscribe to Premium Examiner Statistics for unlimited access to our examiner statistics.
Subscribe to Premium Examiner Statistics for unlimited access to our examiner statistics.
Subscribe to Premium Examiner Statistics for unlimited access to our examiner statistics.
Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.